Noile-Immune Biotech Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1	5	7	316	625	100
Revenue Growth	-88.89%	-28.57%	-97.78%	-49.44%	525.00%	3.09%
Cost of Revenue	52	52	68	42	7	22
Gross Profit	-51	-47	-61	274	618	78
Selling, General & Admin	341	336	429	404	390	330
Research & Development	358	360	579	646	334	514
Other Operating Expenses	54	54	-	-	-	-
Operating Expenses	753	750	1,008	1,050	724	844
Operating Income	-804	-797	-1,069	-776	-106	-766
Interest & Investment Income	8	6	-	-	-	-
Currency Exchange Gain (Loss)	-	-	-	-	5	-
Other Non Operating Income (Expenses)	44	-	107	-352	-283	-27
EBT Excluding Unusual Items	-752	-791	-962	-1,128	-384	-793
Pretax Income	-752	-791	-962	-1,128	-384	-793
Income Tax Expense	2	2	2	2	2	2
Net Income	-754	-793	-964	-1,130	-386	-795
Net Income to Common	-754	-793	-964	-1,130	-386	-795
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	43	43	43	41	39	38
Shares Outstanding (Diluted)	43	43	43	41	39	38
Shares Change	0.03%	0.01%	4.41%	5.87%	2.23%	7.89%
EPS (Basic)	-17.41	-18.31	-22.26	-27.25	-9.85	-20.75
EPS (Diluted)	-17.41	-18.31	-22.26	-27.25	-9.85	-20.75
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-	-	-	86.71%	98.88%	78.00%
Operating Margin	-80400.00%	-15940.00%	-15271.43%	-245.57%	-16.96%	-766.00%
Profit Margin	-75400.00%	-15860.00%	-13771.43%	-357.60%	-61.76%	-795.00%
EBIT	-804	-797	-1,069	-776	-106	-766
EBIT Margin	-	-	-	-245.57%	-16.96%	-